Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older

Exclusion Criteria

• •1. who are unwilling or unable to give written informed consent or assent to participate in the study.
• •2. who are perceived to be unreliable or unavailable for the duration of the study period.
• •3. who have previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s) (licensed or investigational).
• •4. who have received any investigational or non-registered product (drug or vaccine) within 30 days prior to enrolment or who expect to receive an investigational drug or vaccine prior to the completion of the study.
• •5. who have received or who are planning to receive any vaccines (other than routine childhood vaccines) within 30 days before and after administration of study vaccine.
• •(Exception: Influenza vaccine may be administered up to 15 days prior to study vaccination and at least 15 days after study vaccination)
• •6. who have behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.
• •7. who are pregnant or breast feeding (female subjects of appropriate age) or who plan to become pregnant during the course of the study.
• •8. who have any serious acute, chronic or progressive disease (e.g., any history of neoplasm, cancer, diabetes, cardiac disease, autoimmune disease, HIV infection or AIDS, or blood dyscrasias, with signs of cardiac or renal failure or severe malnutrition), who have epilepsy or any progressive neurological disease or history of Guillain-Barre syndrome.
• •9. who have a history of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine components.
• •10. who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
• •11. who are included in study personnel or close family members of personnel conducting this study.